Terms ending in 2040
Every in-force patent on Create Medicines, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,980,836 | Therapeutic Cell Compositions and Methods of Manufacturing and Use Thereof In force · High confidence | Create Medicines, Inc. | In force | High confidence | |
| US 11,013,764 | Engineered Phagocytic Receptor Compositions and Methods of Use Thereof In force · High confidence | Create Medicines, Inc. | In force | High confidence | |
| US 11,026,973 | Engineered Phagocytic Receptor Compositions and Methods of Use Thereof In force · High confidence | Create Medicines, Inc. | In force | High confidence | |
| US 12,599,678 | Methods and Compositions for Genomic Integration In force · Low confidence | Create Medicines, Inc. | In force | Low confidence | |
| US 11,672,874 | Methods and Compositions for Genomic Integration In force · Low confidence | Create Medicines, Inc. | In force | Low confidence | |
| US 12,252,545 | Therapeutic Cell Compositions and Methods of Manufacturing and Use Thereof In force · High confidence | Create Medicines, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.